News
06-06-2010, 10:01 PM
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of clinical data from a Phase Ib/II trial conducted by Roche and Genentech to investigate the safety and preliminary efficacy of trastuzumab-DM1 (T-DM1) used in combination with Roche's investigational antibody, pertuzumab.
More... (http://www.news-medical.net/news/20100607/Phase-IbII-trial-data-for-trastuzumab-DM1-in-combination-with-pertuzumab-presented-at-ASCO-2010.aspx)
More... (http://www.news-medical.net/news/20100607/Phase-IbII-trial-data-for-trastuzumab-DM1-in-combination-with-pertuzumab-presented-at-ASCO-2010.aspx)